Workflow
Amgen(AMGN)
icon
Search documents
Amgen beats on Q2 revenue, slightly raises guidance
CNBC Television· 2025-08-05 20:39
Financial Performance - Amjen's adjusted EPS exceeded expectations at $62 per share, compared to the street's estimate of $529 [1] - Revenue surpassed estimates, reaching $918 billion, against an expected $894 billion [1] - The company is slightly increasing full-year revenue estimates to $35-36 billion, while the street expected $3537 billion [2] - Full-year adjusted EPS guidance is also increasing, but the midpoint is slightly lower than analysts' expectations [3] Product Performance & Market Dynamics - Osteoporosis drug Prolia's revenues met expectations, but it now faces biosimilar competition in the US [1] - Rare disease and cancer drugs showed some strength [2] - There was weakness in inflammation, excluding the drug Otesla [2] Future Outlook - The guidance includes the estimated impact of implemented tariffs but does not anticipate future pharma-specific tariffs or price adjustments [3] - Data from part two of the phase 2 obesity trial is expected in the fourth quarter [3][4]
Amgen(AMGN) - 2025 Q2 - Earnings Call Presentation
2025-08-05 20:30
Financial Performance - Revenues increased by 9% YoY in Q2 2025, reaching $9.179 billion, with product sales contributing $8.771 billion[9, 105] - Non-GAAP EPS grew by 21% YoY in Q2 2025, reaching $6.02[9, 105] - The company invested $1.7 billion in research and development in Q2 2025, an increase of 18% YoY[9] - Free cash flow was $1.9 billion in Q2 2025, compared to $2.2 billion in Q2 2024[107] Product Sales Highlights - Fifteen products achieved double-digit sales growth, including Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA, and TAVNEOS[9, 17] - Repatha sales increased by 31% YoY to $696 million, driven by a 36% increase in volume[12, 23] - EVENITY sales increased by 32% YoY to $518 million, primarily driven by volume growth[12, 23] - UPLIZNA sales increased by 91% YoY to $176 million, driven by 79% volume growth[12, 27] - TEZSPIRE sales increased by 46% YoY to $342 million, driven by volume growth[12, 32] - IMDELLTRA generated $134 million in sales, with a 65% quarter-over-quarter increase[12, 37] Pipeline Development - MariTide: Phase 3 studies are enrolling for obesity and overweight, with or without Type 2 diabetes mellitus, and for adults living with heart failure with preserved or mildly reduced ejection fraction and obesity[42] - UPLIZNA: FDA review of Phase 3 data in generalized myasthenia gravis is ongoing, with a PDUFA date of December 14, 2025[46] - TEZSPIRE: FDA review of Phase 3 data in chronic rhinosinusitis with nasal polyps is ongoing, with a PDUFA date of October 19, 2025[59] - IMDELLTRA: Reduced the risk of death by 40% and significantly extended median OS by more than five months compared to SOC chemotherapy in patients with SCLC who progressed on or after one line of platinum-based chemotherapy[71]
X @Bloomberg
Bloomberg· 2025-08-05 20:15
Amgen boosted its 2025 guidance after quarterly results beat Wall Street’s estimates on the back of strong sales from older medicines https://t.co/ZKgYw1wi8R ...
Amgen(AMGN) - 2025 Q2 - Quarterly Results
2025-08-05 20:03
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Aug. 5, 2025) - Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025. "We're delivering strong performance and reaching more patients with innovative medicines and biosimilars that address serious diseases. We continue to invest in science that enables longer, healthier lives and supports ...
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Prnewswire· 2025-08-05 20:01
Core Insights - Amgen reported strong financial performance for Q2 2025, with total revenues increasing by 9% to $9.2 billion compared to Q2 2024, driven by a 13% volume growth in product sales, despite a 3% decrease in net selling price [5][20] - The company continues to focus on innovative medicines and biosimilars, aiming for sustainable long-term growth [2] Financial Performance - Total revenues for Q2 2025 reached $9.2 billion, a 9% increase from Q2 2024 [5] - GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, while non-GAAP EPS increased 21% from $4.97 to $6.02 [5][16] - GAAP operating income increased from $1.9 billion to $2.7 billion, with an operating margin of 30.3%, up 6.6 percentage points [5][15] - Free cash flow for Q2 2025 was $1.9 billion, down from $2.2 billion in Q2 2024, influenced by deferred tax payments and higher capital expenditures [20] Product Sales Performance - Product sales grew by 9%, with 15 products achieving double-digit sales growth, including Repatha® (31% increase), EVENITY® (32% increase), and UPLIZNA® (91% increase) [5][6] - Prolia® sales decreased by 4% year-over-year to $1.1 billion, attributed to lower net selling prices [6][12] - TEZSPIRE® sales increased by 46% year-over-year to $342 million, driven by volume growth [12][13] Operating Expenses and Margins - Total operating expenses increased by 1% year-over-year, with R&D expenses rising by 21% due to investments in clinical programs [14][15] - The operating margin on a non-GAAP basis increased to 48.9%, reflecting improved operational efficiency [15][19] Cash Flow and Balance Sheet - Operating cash flow for Q2 2025 was $2.3 billion, down from $2.5 billion in Q2 2024 [18] - Cash and cash equivalents totaled $8.0 billion, while debt outstanding was $56.2 billion as of June 30, 2025 [20] Guidance - For the full year 2025, Amgen expects total revenues to be in the range of $35.0 billion to $36.0 billion [18]
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
ZACKS· 2025-08-04 16:51
Industry Overview - The second-quarter earnings season for the drug and biotech sector is in full swing, with major companies like Pfizer, Eli Lilly, Amgen, Gilead Sciences, and Novo Nordisk set to announce results [1] - The earnings season began mid-July with Johnson & Johnson reporting strong results, exceeding estimates for both earnings and sales [1] Company Performance Pfizer (PFE) - Pfizer has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 43.49% [6] - The Zacks Consensus Estimate for second-quarter sales and earnings is $13.78 billion and 58 cents per share, respectively [6] - Higher sales from products like Vyndaqel and Padcev are expected to offset weaker sales from Prevnar and Ibrance [8] Eli Lilly (LLY) - Eli Lilly's performance has been mixed, exceeding earnings expectations in two of the last four quarters, with an average earnings surprise of 6.69% [11] - The Zacks Consensus Estimate for second-quarter sales and earnings stands at $14.75 billion and $5.61 per share, respectively [11] - Strong demand for Mounjaro and Zepbound is anticipated to drive top-line growth [12] Amgen (AMGN) - Amgen has shown strong performance, beating earnings estimates in each of the last four quarters, with an average earnings surprise of 8.34% [14] - The Zacks Consensus Estimate for second-quarter sales and earnings is $8.86 billion and $5.26 per share, respectively [14] - Sales growth is expected to be driven by products like Evenity and Repatha, despite price declines due to higher rebates [15] Gilead Sciences (GILD) - Gilead's performance has been mixed, with earnings beating estimates in three of the last four quarters, averaging a surprise of 16.48% [17] - The Zacks Consensus Estimate for second-quarter sales and earnings is $6.95 billion and $1.95 per share, respectively [17] - Increased demand for HIV therapies like Biktarvy is expected to boost sales [18] Novo Nordisk (NVO) - Novo Nordisk's performance has been mixed, with earnings beating estimates in one of the last four quarters, delivering an average surprise of 0.02% [20] - The Zacks Consensus Estimate for second-quarter sales and earnings is $11.79 billion and 93 cents per share, respectively [20] - The company lowered its 2025 sales and operating profit growth outlook due to weaker momentum in key markets for its semaglutide-based drugs [21]
Buy or Sell Amgen Stock Ahead of Its Earnings?
Forbes· 2025-08-04 15:02
Core Insights - Amgen is scheduled to release its earnings on August 5, 2025, with historical trends indicating a tendency for negative one-day returns post-announcement [2][3] - Analysts project earnings of $5.28 per share and revenue of $8.91 billion, compared to $4.97 per share and $8.39 billion in the same quarter last year [3] - The company has a market capitalization of $160 billion and reported $34 billion in revenue over the past twelve months, resulting in $7.4 billion in operating profits and a net income of $5.9 billion [4] Historical Performance - Over the past five years, Amgen's stock has declined 58% of the time following earnings announcements, with a median drop of -2.8% and a maximum one-day negative return of -7.2% [2][7] - Positive one-day returns occurred approximately 42% of the time, with the percentage increasing to 45% when considering the last three years [7] - The median of the eight positive returns was 3.6%, while the median of the eleven negative returns was -2.8% [7] Trading Strategies - Event-driven traders can utilize historical trends to inform their positioning ahead of earnings releases [6] - A strategy involves assessing the correlation between immediate and medium-term returns post-earnings to guide trading decisions [6][8] - The correlation between one-day and five-day returns can indicate potential trading positions, particularly if the one-day return is positive [8]
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
Prnewswire· 2025-08-01 20:01
Core Points - Amgen's Board of Directors declared a dividend of $2.38 per share for Q3 2025, payable on September 12, 2025, to stockholders of record as of August 22, 2025 [1] - Amgen is a leader in biotechnology, focusing on innovative medicines for serious diseases, with a strong pipeline targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [2] - The company has received multiple accolades, including being named one of the "World's Most Innovative Companies" and "America's Best Large Employers," and is part of the Dow Jones Industrial Average and Nasdaq-100 Index [3] Company Overview - Amgen has over 40 years of experience in the biotechnology industry and utilizes advanced technology and human genetic data to drive innovation [2] - The company is recognized for its commitment to research and development, maintaining a broad and deep pipeline of medicines [2] Recognition and Market Position - In 2024, Amgen was recognized by Fast Company and Forbes for its innovation and employer status, highlighting its strong market position [3] - As a component of major stock indices, Amgen is considered one of the largest and most innovative non-financial companies [3]
特朗普向药企“开刀” 要求60天内降低美国药价
智通财经网· 2025-07-31 22:18
Group 1 - President Trump has sent letters to 17 major pharmaceutical companies, demanding specific actions to lower drug prices in the U.S. within 60 days, or he will use "all available means" to protect American families from "price gouging" [1][2] - The companies that received the letters include Pfizer, Novo Nordisk, Johnson & Johnson, and others, with a focus on commitments such as providing "most favored nation" pricing for Medicaid patients and direct sales to consumers [1][2] - Trump highlighted that U.S. drug prices are significantly higher than those in other developed countries, with average prescription drug prices being 2 to 3 times higher, and some drugs up to 10 times more expensive [2] Group 2 - Following the announcement, stock prices of several pharmaceutical companies dropped, with Sanofi falling over 8%, and others like Bristol-Myers Squibb and Novo Nordisk declining nearly 5% [2] - The Pharmaceutical Research and Manufacturers of America criticized the introduction of "foreign price controls," arguing it would undermine U.S. innovation and harm patients and workers [3] - Companies like Pfizer and Novartis stated they are working on solutions to make medications more affordable for American patients, with AstraZeneca considering price reductions and direct sales models [3]
AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
Prnewswire· 2025-07-31 20:01
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X, LinkedIn ...